ArticleAnnals of Indian Academy of Neurology2025
Evaluating Therapeutic Outcomes in Spinal Muscular Atrophy: An Indian Experience.
Article in Annals of Indian Academy of Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Onasemnogene Abeparvovec in Early-Onset Spinal Muscular Atrophy: An Indian Experience.Annals of Indian Academy of Neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesSpinal muscular atrophy (SMA) is a progressive neuromuscular disorder that leads to anterior horn cell loss. Recent advancements in disease-modifying therapies (DMTs) offer promising new treatment options. This study aimed to evaluate and compare the efficacy and safety profiles of risdiplam, nusinersen, and gene therapy in SMA patients with different disease severities in an Indian cohort.
methodsAn observational retrospective study was conducted between June 2020 and October 2023, involving 47 genetically confirmed SMA patients (types 1-3). Participants received treatment with risdiplam (n = 11), nusinersen (Spinraza) (n = 25), gene therapy (n = 9), and combination therapy/bridging with risdiplam and gene therapy (n = 2). Motor function was assessed using the Hammersmith functional motor scale expanded (HFMSE) and the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders over 6 monthly follow-up intervals. Safety was monitored by tracking adverse events. As the majority were SMA types 2/3, the primary outcome was measured using HFMSE scores, with improvement defined as an absolute change in HFMSE score of ≥3 points from the baseline (first visit) to the third visit (completion of 12 months).
resultsThere were 47 patients aged 1-23 years (28 girls and 19 boys), who received various DMTs, with a minimum of three visits considered for analysis. All treatments resulted in motor function improvements. Gene therapy showed the most substantial benefit, with a median HFMSE score increase of 4 (2-15) compared to 3.5 (0-7.25) for nusinersen and 2.5 (0.25-8.0) for risdiplam. A positive correlation was observed between the number of SMN2 copies and baseline disease severity (Spearman's correlation = 0.57; P = 0.001). Safety profiles were consistent across all therapies, with no new concerns.
conclusionsThis study underscores the efficacy of contemporary SMA treatments and highlights the potential benefits of personalized treatment strategies, despite variability in disease severity. Future research should focus on optimizing individualized therapy approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.